Asia Pacific Biopharma Excipients Market Size, Share & Trends Analysis Report By Product (Solubilizers & Surfactants/Emulsifiers, Polyols, Carbohydrates, Specialty Biopharma Excipients), By Country, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Artificial Ventilation And Anesthesia Masks Market Growth & Trends
The global artificial ventilation and anesthesia masks market size is anticipated to reach USD 3.30 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.1% from 2024 to 2030. Key factors attributing to market growth include rising number of operation and emergency room procedures coupled with growing demand novel products which can be used to carry out intubation process without removing the oxygen mask. Increase in the target disease has a direct impact on the number of operation room, emergency and intensive care procedures and is expected to boost usage rates of ventilation masks over the forecast period.
Increasing geriatric population is a major factor increasing the prevalence rate of several diseases. Additionally, growing prevalence of sleep apnea is one of the most significant growth drivers for these anesthesia and ventilation masks over the forecast period.
According to statistics published by the National Sleep Foundation in 2012, around 40 million Americans were affected by chronic sleep disorders. Furthermore, these patients are at a high risk of visiting emergency department and intensive care units, and as a consequence are expected to increase the demand of ventilation masks in the next seven years.
The market dynamics indicate that various players operating in this space compete on the basis of product specification and prices. The technology used to manufacture, quality of the product, and patient comfort are the key variables expected to impact the usage of these products. The healthcare providers assess the risk to the patient and determine the need to use invasive ventilation or non-invasive ventilation. The use of non invasive masks in accident and trauma cases, lung failure and other emergency cases is a key factor contributing to the high usage rates of these products.
The market is segmented on the basis of application as operation room, intensive care units, emergency room, dental, and home care. In 2014 operating room held the maximum share of over 58% for low risk procedures and is expected to be the largest segment in the next seven years. Increase in insurance penetration, number of hospitals and dental centers to tap the high unmet needs in emerging economies is a key factor expected to boost the surgical volume and therefore these factors are expected to increase the demand for ventilation masks over the forecast period.
Artificial Ventilation And Anesthesia Masks Market Report Highlights
Artificial Ventilation And Anesthesia Masks Market Growth & Trends
The global artificial ventilation and anesthesia masks market size is anticipated to reach USD 3.30 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.1% from 2024 to 2030. Key factors attributing to market growth include rising number of operation and emergency room procedures coupled with growing demand novel products which can be used to carry out intubation process without removing the oxygen mask. Increase in the target disease has a direct impact on the number of operation room, emergency and intensive care procedures and is expected to boost usage rates of ventilation masks over the forecast period.
Increasing geriatric population is a major factor increasing the prevalence rate of several diseases. Additionally, growing prevalence of sleep apnea is one of the most significant growth drivers for these anesthesia and ventilation masks over the forecast period.
According to statistics published by the National Sleep Foundation in 2012, around 40 million Americans were affected by chronic sleep disorders. Furthermore, these patients are at a high risk of visiting emergency department and intensive care units, and as a consequence are expected to increase the demand of ventilation masks in the next seven years.
The market dynamics indicate that various players operating in this space compete on the basis of product specification and prices. The technology used to manufacture, quality of the product, and patient comfort are the key variables expected to impact the usage of these products. The healthcare providers assess the risk to the patient and determine the need to use invasive ventilation or non-invasive ventilation. The use of non invasive masks in accident and trauma cases, lung failure and other emergency cases is a key factor contributing to the high usage rates of these products.
The market is segmented on the basis of application as operation room, intensive care units, emergency room, dental, and home care. In 2014 operating room held the maximum share of over 58% for low risk procedures and is expected to be the largest segment in the next seven years. Increase in insurance penetration, number of hospitals and dental centers to tap the high unmet needs in emerging economies is a key factor expected to boost the surgical volume and therefore these factors are expected to increase the demand for ventilation masks over the forecast period.
Artificial Ventilation And Anesthesia Masks Market Report Highlights
- Disposable masks accounted for the largest revenue share of 68.0% in 2023. The dominance of disposable masks in the medical industry is driven by their cost-effectiveness, user convenience, reduced infection risk, and adherence to legal requirements.
- The operating rooms application segment dominated the market with a revenue share of 32.0% in 2023. Operating rooms have modern working ventilation systems and devices for anesthesia where one is able to control in detail the amount of air circulation and the concentration of the anesthetic mixture.
- Reusable masks are expected to grow significantly over the forecast period, registering a CAGR of 4.6%. Reusable masks offer a cost-effective solution for hospitals, as they can be cleaned and reused, reducing waste and minimizing costs.
- North America artificial ventilation and anesthesia masks market dominated the global artificial ventilation and anesthesia masks market with a revenue share of 36.1% in 2023.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. ASIA PACIFIC BIOPHARMA EXCIPIENT MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Asia Pacific Biopharma Excipient Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. ASIA PACIFIC BIOPHARMA EXCIPIENT MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Asia Pacific Biopharma Excipient Market: Product Movement Analysis, USD Million, 2023 & 2030
4.3. Solubilizers & Surfactants/Emulsifiers
4.3.1. Solubilizers & Surfactants/Emulsifiers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Polyols
4.4.1. Polyols Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Carbohydrates
4.5.1. Carbohydrates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Specialty Biopharma Excipients/Others
4.6.1. Specialty Biopharma Excipients/Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. ASIA PACIFIC BIOPHARMA EXCIPIENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
5.1. Asia Pacific Biopharma Excipient Market Share, By Region, 2023 & 2030, USD Million
5.2. Asia Pacific
5.2.1. Asia Pacific Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Japan
5.2.2.1. Japan Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.3. China
5.2.3.1. China Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.4. India
5.2.4.1. India Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.5. Malaysia
5.2.5.1. Malaysia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.6. South Korea
5.2.6.1. South Korea Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.7. Philippines
5.2.7.1. Philippines Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.8. New Zealand
5.2.8.1. New Zealand Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.9. Australia
5.2.9.1. Australia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.10. Singapore
5.2.10.1. Singapore Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.11. Indonesia
5.2.11.1. Indonesia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1. Recent Developments & Impact Analysis by Key Market Participants
6.2. Company Categorization
6.3. Company Heat Map Analysis
6.4. Company Profiles
6.4.1. Signet Excipients Pvt. Ltd.
6.4.1.1. Participant’s Overview
6.4.1.2. Financial Performance
6.4.1.3. Product Benchmarking
6.4.1.4. Recent Developments/ Strategic Initiatives
6.4.2. ABITEC
6.4.2.1. Participant’s Overview
6.4.2.2. Financial Performance
6.4.2.3. Product Benchmarking
6.4.2.4. Recent Developments/ Strategic Initiatives
6.4.3. Sigachi Industries.
6.4.3.1. Participant’s Overview
6.4.3.2. Financial Performance
6.4.3.3. Product Benchmarking
6.4.3.4. Recent Developments/ Strategic Initiatives
6.4.4. Roquette Fr?res
6.4.4.1. Participant’s Overview
6.4.4.2. Financial Performance
6.4.4.3. Product Benchmarking
6.4.4.4. Recent Developments/ Strategic Initiatives
6.4.5. Colorcon
6.4.5.1. Participant’s Overview
6.4.5.2. Financial Performance
6.4.5.3. Product Benchmarking
6.4.5.4. Recent Developments/ Strategic Initiatives
6.4.6. Meggle GmbH & Co. KG
6.4.6.1. Participant’s Overview
6.4.6.2. Financial Performance
6.4.6.3. Product Benchmarking
6.4.6.4. Recent Developments/ Strategic Initiatives
6.4.7. CLARIANT
6.4.7.1. Participant’s Overview
6.4.7.2. Financial Performance
6.4.7.3. Product Benchmarking
6.4.7.4. Recent Developments/ Strategic Initiatives
6.4.8. DFE Pharma
6.4.8.1. Participant’s Overview
6.4.8.2. Financial Performance
6.4.8.3. Product Benchmarking
6.4.8.4. Recent Developments/ Strategic Initiatives
6.4.9. SPI Pharma
6.4.9.1. Participant’s Overview
6.4.9.2. Financial Performance
6.4.9.3. Product Benchmarking
6.4.9.4. Recent Developments/ Strategic Initiatives
6.4.10. IMCD.
6.4.10.1. Participant’s Overview
6.4.10.2. Financial Performance
6.4.10.3. Product Benchmarking
6.4.10.4. Recent Developments/ Strategic Initiatives
6.4.11. Spectrum Chemical
6.4.11.1. Participant’s Overview
6.4.11.2. Financial Performance
6.4.11.3. Product Benchmarking
6.4.11.4. Recent Developments/ Strategic Initiatives
6.4.12. Pharmonix
6.4.12.1. Participant’s Overview
6.4.12.2. Financial Performance
6.4.12.3. Product Benchmarking
6.4.12.4. Recent Developments/ Strategic Initiatives
6.4.13. BASF SE
6.4.13.1. Participant’s Overview
6.4.13.2. Financial Performance
6.4.13.3. Product Benchmarking
6.4.13.4. Recent Developments/ Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. ASIA PACIFIC BIOPHARMA EXCIPIENT MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Asia Pacific Biopharma Excipient Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. ASIA PACIFIC BIOPHARMA EXCIPIENT MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Asia Pacific Biopharma Excipient Market: Product Movement Analysis, USD Million, 2023 & 2030
4.3. Solubilizers & Surfactants/Emulsifiers
4.3.1. Solubilizers & Surfactants/Emulsifiers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Polyols
4.4.1. Polyols Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Carbohydrates
4.5.1. Carbohydrates Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Specialty Biopharma Excipients/Others
4.6.1. Specialty Biopharma Excipients/Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. ASIA PACIFIC BIOPHARMA EXCIPIENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
5.1. Asia Pacific Biopharma Excipient Market Share, By Region, 2023 & 2030, USD Million
5.2. Asia Pacific
5.2.1. Asia Pacific Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Japan
5.2.2.1. Japan Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.3. China
5.2.3.1. China Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.4. India
5.2.4.1. India Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.5. Malaysia
5.2.5.1. Malaysia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.6. South Korea
5.2.6.1. South Korea Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.7. Philippines
5.2.7.1. Philippines Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.8. New Zealand
5.2.8.1. New Zealand Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.9. Australia
5.2.9.1. Australia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.10. Singapore
5.2.10.1. Singapore Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.11. Indonesia
5.2.11.1. Indonesia Biopharma Excipient Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1. Recent Developments & Impact Analysis by Key Market Participants
6.2. Company Categorization
6.3. Company Heat Map Analysis
6.4. Company Profiles
6.4.1. Signet Excipients Pvt. Ltd.
6.4.1.1. Participant’s Overview
6.4.1.2. Financial Performance
6.4.1.3. Product Benchmarking
6.4.1.4. Recent Developments/ Strategic Initiatives
6.4.2. ABITEC
6.4.2.1. Participant’s Overview
6.4.2.2. Financial Performance
6.4.2.3. Product Benchmarking
6.4.2.4. Recent Developments/ Strategic Initiatives
6.4.3. Sigachi Industries.
6.4.3.1. Participant’s Overview
6.4.3.2. Financial Performance
6.4.3.3. Product Benchmarking
6.4.3.4. Recent Developments/ Strategic Initiatives
6.4.4. Roquette Fr?res
6.4.4.1. Participant’s Overview
6.4.4.2. Financial Performance
6.4.4.3. Product Benchmarking
6.4.4.4. Recent Developments/ Strategic Initiatives
6.4.5. Colorcon
6.4.5.1. Participant’s Overview
6.4.5.2. Financial Performance
6.4.5.3. Product Benchmarking
6.4.5.4. Recent Developments/ Strategic Initiatives
6.4.6. Meggle GmbH & Co. KG
6.4.6.1. Participant’s Overview
6.4.6.2. Financial Performance
6.4.6.3. Product Benchmarking
6.4.6.4. Recent Developments/ Strategic Initiatives
6.4.7. CLARIANT
6.4.7.1. Participant’s Overview
6.4.7.2. Financial Performance
6.4.7.3. Product Benchmarking
6.4.7.4. Recent Developments/ Strategic Initiatives
6.4.8. DFE Pharma
6.4.8.1. Participant’s Overview
6.4.8.2. Financial Performance
6.4.8.3. Product Benchmarking
6.4.8.4. Recent Developments/ Strategic Initiatives
6.4.9. SPI Pharma
6.4.9.1. Participant’s Overview
6.4.9.2. Financial Performance
6.4.9.3. Product Benchmarking
6.4.9.4. Recent Developments/ Strategic Initiatives
6.4.10. IMCD.
6.4.10.1. Participant’s Overview
6.4.10.2. Financial Performance
6.4.10.3. Product Benchmarking
6.4.10.4. Recent Developments/ Strategic Initiatives
6.4.11. Spectrum Chemical
6.4.11.1. Participant’s Overview
6.4.11.2. Financial Performance
6.4.11.3. Product Benchmarking
6.4.11.4. Recent Developments/ Strategic Initiatives
6.4.12. Pharmonix
6.4.12.1. Participant’s Overview
6.4.12.2. Financial Performance
6.4.12.3. Product Benchmarking
6.4.12.4. Recent Developments/ Strategic Initiatives
6.4.13. BASF SE
6.4.13.1. Participant’s Overview
6.4.13.2. Financial Performance
6.4.13.3. Product Benchmarking
6.4.13.4. Recent Developments/ Strategic Initiatives
